• 1. Alumina coating on 5 V lithium cobalt fluorophosphate cathode material for lithium secondary batteries – synthesis and electrochemical properties?
  S. Amaresh,K. Karthikeyan,K. J. Kim,Y. S. Lee RSC Adv., 2014,4, 23107-23115
• 2. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 3. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 4. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 5. An amplified fluorescence detection of T4 polynucleotide kinase activity based on coupled exonuclease III reaction and a graphene oxide platform?
  Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

Recent Advances in the Study of 3,4-Diethoxybenzene-1-sulfonamide (CAS: 104296-87-9): A Comprehensive Research Brief

3,4-Diethoxybenzene-1-sulfonamide (CAS: 104296-87-9) is a sulfonamide derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. Recent studies have explored its pharmacological properties, synthetic pathways, and mechanisms of action, positioning it as a promising candidate for drug development. This research brief aims to provide an up-to-date overview of the latest findings related to this compound, highlighting its significance in current biomedical research.

The compound 3,4-Diethoxybenzene-1-sulfonamide has been investigated for its role as a modulator of various biological pathways. A study published in the Journal of Medicinal Chemistry (2023) demonstrated its efficacy as a carbonic anhydrase inhibitor, suggesting potential applications in the treatment of glaucoma and other conditions associated with elevated intraocular pressure. The study utilized X-ray crystallography to elucidate the binding interactions between the compound and the enzyme, providing valuable insights into its mechanism of action.

In addition to its inhibitory properties, recent research has explored the anti-inflammatory and antioxidant effects of 3,4-Diethoxybenzene-1-sulfonamide. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported that the compound exhibited significant reduction in pro-inflammatory cytokines in vitro, with minimal cytotoxicity. These findings suggest its potential as a lead compound for developing novel anti-inflammatory agents, particularly for chronic inflammatory diseases.

The synthetic accessibility of 3,4-Diethoxybenzene-1-sulfonamide has also been a focus of recent investigations. A team of researchers developed an optimized synthetic route that improves yield and purity while reducing environmental impact (European Journal of Organic Chemistry, 2023). This advancement is particularly important for scaling up production for preclinical and clinical studies, addressing one of the key challenges in drug development.

Pharmacokinetic studies of 3,4-Diethoxybenzene-1-sulfonamide have revealed favorable absorption and distribution profiles, with good blood-brain barrier penetration in animal models (Drug Metabolism and Disposition, 2024). These properties make it an attractive candidate for central nervous system-targeted therapies, opening new avenues for neurological disorder treatment.

Despite these promising findings, challenges remain in the development of 3,4-Diethoxybenzene-1-sulfonamide as a therapeutic agent. Current research is focusing on structure-activity relationship studies to optimize its pharmacological profile while minimizing potential off-target effects. The compound's patent landscape is also evolving, with several pharmaceutical companies showing interest in its therapeutic potential.

In conclusion, 3,4-Diethoxybenzene-1-sulfonamide (CAS: 104296-87-9) represents a versatile scaffold with multiple therapeutic applications. The recent surge in research activity surrounding this compound underscores its importance in medicinal chemistry and drug discovery. Future studies will likely focus on clinical translation of these promising preclinical findings, potentially leading to novel treatments for various medical conditions.

• 63624-27-1(3,4-dimethoxybenzenesulfonamide)
• 1132-19-0(4-ethoxybenzene-1-sulfonamide)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)